Yvette van Kooyk

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/477241/publications.pdf

Version: 2024-02-01

113
papers

9,915
citations

53794

45
h-index

37204

96
g-index

117
all docs

117
docs citations

117
times ranked

10751
citing authors

#	Article	IF	Citations
1	Identification of DC-SIGN, a Novel Dendritic Cellâ€“Specific ICAM-3 Receptor that Supports Primary Immune Responses. Cell, 2000, 100, 575-585.	28.9	1,558
2	Mycobacteria Target DC-SIGN to Suppress Dendritic Cell Function. Journal of Experimental Medicine, 2003, 197, 7-17.	8.5	971
3	Protein-glycan interactions in the control of innate and adaptive immune responses. Nature Immunology, 2008, 9, 593-601.	14.5	660
4	The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells. Journal of Immunology, 2002, 168, 2118-2126.	0.8	568
5	Cutting Edge: Carbohydrate Profiling Identifies New Pathogens That Interact with Dendritic Cell-Specific ICAM-3-Grabbing Nonintegrin on Dendritic Cells. Journal of Immunology, 2003, 170, 1635-1639.	0.8	402
6	The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nature Reviews Immunology, 2018, 18, 204-211.	22.7	303
7	<i>Helicobacter pylori</i>Modulates the T Helper Cell 1/T Helper Cell 2 Balance through Phase-variable Interaction between Lipopolysaccharide and DC-SIGN. Journal of Experimental Medicine, 2004, 200, 979-990.	8.5	290
8	Neuroinflammation: Microglia and T Cells Get Ready to Tango. Frontiers in Immunology, 2017, 8, 1905.	4.8	257
9	Specificity of DC-SIGN for mannose- and fucose-containing glycans. FEBS Letters, 2006, 580, 6123-6131.	2.8	241
10	Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions. Frontiers in Immunology, 2018, 9, 2807.	4.8	188
11	The physiological role of DC-SIGN: A tale of mice and men. Trends in Immunology, 2013, 34, 482-486.	6.8	167
12	Identification of Different Binding Sites in the Dendritic Cell-specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1. Journal of Biological Chemistry, 2002, 277, 11314-11320.	3.4	165
13	Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. Journal of Controlled Release, 2012, 160, 88-95.	9.9	158
14	Sweet preferences of MGL: carbohydrate specificity and function. Trends in Immunology, 2008, 29, 83-90.	6.8	140
15	Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3329-3334.	7.1	135
16	Dendritic Cell Maturation Results in Pronounced Changes in Glycan Expression Affecting Recognition by Siglecs and Galectins. Journal of Immunology, 2007, 179, 8216-8224.	0.8	117
17	Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nature Communications, 2021, 12, 1270.	12.8	111
18	Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Molecular Immunology, 2009, 47, 164-174.	2.2	109

#	Article	IF	Citations
19	Understanding the Biology of Antigen Cross-Presentation for the Design of Vaccines Against Cancer. Frontiers in Immunology, 2014, 5, 149.	4.8	106
20	Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8+ T Cell Cross-Priming. Cell Reports, 2018, 22, 1484-1495.	6.4	106
21	Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Molecular Immunology, 2013, 55, 143-145.	2.2	105
22	Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy. Frontiers in Oncology, 2018, 8, 39.	2.8	104
23	Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells. Oncotarget, 2016, 7, 8771-8782.	1.8	99
24	Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells. Molecular Immunology, 2013, 53, 387-397.	2.2	96
25	MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-Î± secretion. Journal of Leukocyte Biology, 2013, 94, 315-323.	3.3	91
26	Characterization of murine MGL1 and MGL2 C-type lectins: Distinct glycan specificities and tumor binding properties. Molecular Immunology, 2009, 46, 1240-1249.	2.2	86
27	Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8+ T cells. Acta Biomaterialia, 2019, 91, 248-257.	8.3	76
28	Constitutive Chemokine Production Results in Activation of Leukocyte Function-Associated Antigen-1 on Adult T-Cell Leukemia Cells. Blood, 1998, 91, 3909-3919.	1.4	75
29	Glycan modification of glioblastomaâ€derived extracellular vesicles enhances receptorâ€mediated targeting of dendritic cells. Journal of Extracellular Vesicles, 2019, 8, 1648995.	12.2	72
30	Optical clearing and fluorescence deep-tissue imaging for 3D quantitative analysis of the brain tumor microenvironment. Angiogenesis, 2017, 20, 533-546.	7.2	71
31	Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens. Journal of Controlled Release, 2015, 203, 67-76.	9.9	68
32	Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. Journal of Leukocyte Biology, 2017, 102, 1017-1034.	3.3	67
33	MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses. Journal of Controlled Release, 2015, 216, 37-46.	9.9	64
34	Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8. Journal of Extracellular Vesicles, 2018, 7, 1446660.	12.2	64
35	â€˜Dressed for successâ€™ C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells. Current Opinion in Immunology, 2011, 23, 131-137.	5.5	63
36	Novel insights into the immunomodulatory role of the dendritic cell and macrophage-expressed C-type lectin MGL. Immunobiology, 2015, 220, 185-192.	1.9	62

#	Article	IF	Citations
37	<i>Trypanosoma cruzi</i> Infection Imparts a Regulatory Program in Dendritic Cells and T Cells via Galectin-1â€“Dependent Mechanisms. Journal of Immunology, 2015, 195, 3311-3324.	0.8	59
38	Skin-Resident Antigen-Presenting Cells: Instruction Manual for Vaccine Development. Frontiers in Immunology, 2013, 4, 157.	4.8	57
39	Glioblastomas exploit truncated O <i>-</i> linked glycans for local and distant immune modulation via the macrophage galactose-type lectin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3693-3703.	7.1	57
40	Pairing <i>Bacteroides vulgatus</i> LPS Structure with Its Immunomodulatory Effects on Human Cellular Models. ACS Central Science, 2020, 6, 1602-1616.	11.3	55
41	Selective tumor antigen vaccine delivery to human CD169 ⁺ antigen-presenting cells using ganglioside-liposomes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27528-27539.	7.1	54
42	MGLâ€mediated internalization and antigen presentation by dendritic cells: A role for tyrosineâ€5. European Journal of Immunology, 2007, 37, 2075-2081.	2.9	52
43	Design of neoâ€glycoconjugates that target the mannose receptor and enhance TLRâ€independent crossâ€presentation and Th1 polarization. European Journal of Immunology, 2011, 41, 916-925.	2.9	49
44	Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets. Theranostics, 2019, 9, 5797-5809.	10.0	48
45	DCIR interacts with ligands from both endogenous and pathogenic origin. Immunology Letters, 2014, 158, 33-41.	2.5	47
46	Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. Cancers, 2019, 11, 1266.	3.7	47
47	Glycan modification of the tumor antigen gp100 targets DCâ€SIGN to enhance dendritic cell induced antigen presentation to T cells. International Journal of Cancer, 2008, 122, 839-846.	5.1	46
48	Tolerogenic Immunotherapy: Targeting DC Surface Receptors to Induce Antigen-Specific Tolerance. Frontiers in Immunology, 2021, 12, 643240.	4.8	44
49	Human Milk Blocks DC-SIGNâ€“Pathogen Interaction via MUC1. Frontiers in Immunology, 2015, 6, 112.	4.8	43
50	Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I. Frontiers in Immunology, 2018, 9, 1231.	4.8	43
51	Controlled release of a model vaccine by nanoporous ceramic microneedle arrays. International Journal of Pharmaceutics, 2015, 491, 375-383.	5.2	42
52	Tn Antigen Expression Contributes to an Immune Suppressive Microenvironment and Drives Tumor Growth in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 1622.	2.8	41
53	MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. Oncotarget, 2015, 6, 26278-26290.	1.8	39
54	Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. , 2020, 8, e000588.		38

#	ARTICLE	IF	CITATIONS
55	Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells. Cellular and Molecular Immunology, 2017, 14, 360-370.	10.5	37
56	Systematic Dual Targeting of Dendritic Cell C-Type Lectin Receptor DC-SIGN and TLR7 Using a Trifunctional Mannosylated Antigen. Frontiers in Chemistry, 2019, 7, 650.	3.6	37
57	Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Oncotarget, 0, 7, 41053-41066.	1.8	37
58	Internalization and presentation of myelin antigens by the brain endothelium guides antigen-specific T cell migration. ELife, 2016, 5, .	6.0	37
59	In situ Delivery of Antigen to DC-SIGN + CD14 + Dermal Dendritic Cells Results in Enhanced CD8 + T-Cell Responses. Journal of Investigative Dermatology, 2015, 135, 2228-2236.	0.7	35
60	Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity. Frontiers in Immunology, 2018, 9, 990.	4.8	35
61	Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. OncoImmunology, 2013, 2, e23040.	4.6	34
62	Fasciola hepatica glycoconjugates immuneregulate dendritic cells through the Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin inducing T cell anergy. Scientific Reports, 2017, 7, 46748.	3.3	34
63	Disruption of sialic acid metabolism drives tumor growth by augmenting CD8⁺ T cell apoptosis. International Journal of Cancer, 2019, 144, 2290-2302.	5.1	34
64	Online nanoliquid chromatographyâ€“mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis. Analytical Biochemistry, 2012, 423, 153-162.	2.4	33
65	Antibody-Opsonized Bacteria Evoke an Inflammatory Dendritic Cell Phenotype and Polyfunctional Th Cells by Cross-Talk between TLRs and FcRs. Journal of Immunology, 2015, 194, 1856-1866.	0.8	33
66	CD169 Defines Activated CD14+ Monocytes With Enhanced CD8+ T Cell Activation Capacity. Frontiers in Immunology, 2021, 12, 697840.	4.8	33
67	Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. OncoImmunology, 2015, 4, e970462.	4.6	30
68	DC-SIGN: The Strange Case of Dr. Jekyll and Mr. Hyde. Immunity, 2015, 42, 983-985.	14.3	30
69	Fasciola hepatica Immune Regulates CD11c+ Cells by Interacting with the Macrophage Gal/GalNAc Lectin. Frontiers in Immunology, 2017, 8, 264.	4.8	29
70	Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression. Frontiers in Immunology, 2018, 9, 1990.	4.8	29
71	Human T Cell Activation Results in Extracellular Signal-regulated Kinase (ERK)-Calcineurin-dependent Exposure of Tn Antigen on the Cell Surface and Binding of the Macrophage Galactose-type Lectin (MGL)*. Journal of Biological Chemistry, 2013, 288, 27519-27532.	3.4	27
72	Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses. Frontiers in Immunology, 2020, 11, 990.	4.8	27

#	Article	IF	Citations
73	Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance. Frontiers in Immunology, 2021, 12, 674048.	4.8	26
74	Glycan modification of antigen alters its intracellular routing in dendritic cells, promoting priming of T cells. ELife, 2016, 5, .	6.0	24
75	The Consequences of Multiple Simultaneous C-Type Lectinâ€“Ligand Interactions: DCIR Alters the Endo-Lysosomal Routing of DC-SIGN. Frontiers in Immunology, 2015, 6, 87.	4.8	23
76	Macrophage galactose-type lectin (MGL) is induced on M2 microglia and participates in the resolution phase of autoimmune neuroinflammation. Journal of Neuroinflammation, 2019, 16, 130.	7.2	23
77	Activation of the C-Type Lectin MGL by Terminal GalNAc Ligands Reduces the Glycolytic Activity of Human Dendritic Cells. Frontiers in Immunology, 2020, 11, 305.	4.8	22
78	A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources. Clinical Chemistry, 2016, 62, 1390-1400.	3.2	21
79	Activation of CD8+ T Cell Responses after Melanoma Antigen Targeting to CD169+ Antigen Presenting Cells in Mice and Humans. Cancers, 2019, 11, 183.	3.7	21
80	Liposomal Nanovaccine Containing Î±-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1. Vaccines, 2021, 9, 56.	4.4	20
81	New roles for CD14 and ILâ€Î² linking inflammatory dendritic cells to ILâ€17 production in memory CD4 + T cells. Immunology and Cell Biology, 2016, 94, 907-916.	2.3	19
82	Targeting Mycobacterium tuberculosis Antigens to Dendritic Cells via the DC-Specific-ICAM3-Grabbing-Nonintegrin Receptor Induces Strong T-Helper 1 Immune Responses. Frontiers in Immunology, 2018, 9, 471.	4.8	19
83	Analytical Tools for the Study of Cellular Glycosylation in the Immune System. Frontiers in Immunology, 2013, 4, 451.	4.8	18
84	Phenotypic and Functional Properties of Human Steady State CD14+ and CD1a+ Antigen Presenting Cells and Epidermal Langerhans Cells. PLoS ONE, 2015, 10, e0143519.	2.5	18
85	Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma. Frontiers in Immunology, 2018, 9, 1997.	4.8	16
86	<i>C</i>-Mannosyl Lysine for Solid Phase Assembly of Mannosylated Peptide Conjugate Cancer Vaccines. ACS Chemical Biology, 2020, 15, 728-739.	3.4	16
87	Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages. Pharmaceutics, 2020, 12, 1138.	4.5	15
88	Targeting of the C-Type Lectin Receptor Langerin Using Bifunctional Mannosylated Antigens. Frontiers in Cell and Developmental Biology, 2020, 8, 556.	3.7	13
89	Immobilization of Î²-galactosidase and Î±-mannosidase onto magnetic nanoparticles: A strategy for increasing the potentiality of valuable glycomic tools for glycosylation analysis and biological role determination of glycoconjugates. Enzyme and Microbial Technology, 2018, 117, 45-55.	3.2	12
90	Uptake Kinetics Of Liposomal Formulations of Differing Charge Influences Development of in Vivo Dendritic Cell Immunotherapy. Journal of Pharmaceutical Sciences, 2022, 111, 1081-1091.	3.3	12

#	ARTICLE	IF	CITATIONS
91	Highly glycosylated tumour antigens: interactions with the immune system. Biochemical Society Transactions, 2011, 39, 388-392.	3.4	9
92	Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells. Current Opinion in Chemical Biology, 2019, 53, 167-172.	6.1	9
93	Bacterial inclusion bodies function as vehicles for dendritic cell-mediated T cell responses. Cellular and Molecular Immunology, 2020, 17, 415-417.	10.5	9
94	Distinct antigen uptake receptors route to the same storage compartments for crossâ€presentation in dendritic cells. Immunology, 2021, 164, 494-506.	4.4	8
95	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. Communications Biology, 2022, 5, 41.	4.4	8
96	Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity. Biomaterials, 2020, 262, 120342.	11.4	7
97	Î±2-3 Sialic acid binding and uptake by human monocyte-derived dendritic cells alters metabolism and cytokine release and initiates tolerizing T cell programming. Immunotherapy Advances, 2021, 1, .	3.0	7
98	Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses. Frontiers in Immunology, 2022, 13, 842241.	4.8	7
99	Immune involvement of the contralateral hemisphere in a glioblastoma mouse model. , 2020, 8, e000323.		6
100	Myeloid-Specific Acly Deletion Alters Macrophage Phenotype In Vitro and In Vivo without Affecting Tumor Growth. Cancers, 2021, 13, 3054.	3.7	6
101	A new cellular target for <i>Yersinia pestis</i>. Immunology and Cell Biology, 2015, 93, 769-770.	2.3	3
102	Apoptotic vesicles as tumor vaccine. Immunotherapy, 2016, 8, 5-8.	2.0	3
103	Next-generation malarial vaccines. Nature Materials, 2019, 18, 94-96.	27.5	3
104	Synthesis of Asparagine Derivatives Harboring a Lewis X Type DCâ€SIGN Ligand and Evaluation of their Impact on Immunomodulation in Multiple Sclerosis. Chemistry - A European Journal, 2021, 27, 2742-2752.	3.3	3
105	Quantitative Phosphoproteomic Analysis Reveals Dendritic Cell- Specific STAT Signaling After Î±2-3â€“Linked Sialic Acid Ligand Binding. Frontiers in Immunology, 2021, 12, 673454.	4.8	3
106	Palmitoylated antigens for the induction of anti-tumor CD8+ TÂcells and enhanced tumor recognition. Molecular Therapy - Oncolytics, 2021, 21, 315-328.	4.4	3
107	Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future. OncoImmunology, 2016, 5, e1214791.	4.6	2
108	C-Type Lectins in Innate Immunity to Pathogens. Trends in Glycoscience and Glycotechnology, 2004, 16, 265-279.	0.1	2

#	Article	IF	Citations
109	TMIC-28. GLIOBLASTOMA EXPLOITS CELL SURFACE GLYCOSYLATION-MEDIATED IMMUNE REGULATORY CIRCUITS FOR IMMUNE ESCAPE. Neuro-Oncology, 2018, 20, vi262-vi262.	1.2	1
110	EXTH-21. REPURPOSING GLIOBLASTOMA EXOSOMES AS PERSONALIZED MULTI-ANTIGENIC ANTI-TUMOR VACCINE. Neuro-Oncology, 2018, 20, vi89-vi89.	1.2	1
111	Human C-Type Lectins, MGL, DC-SIGN and Langerin, Their Interactions With Endogenous and Exogenous Ligand Patterns. , 2021, , 425-441.		1
112	IMMU-20. SINGLE CELL CYTOMICS OF PERIPHERAL BLOOD MONONUCLEAR CELLS REVEALS NEW AVENUES FOR GLIOMA IMMUNOTHERAPY. Neuro-Oncology, 2018, 20, vi125-vi125.	1.2	0
113	IMMU-30. HIGH-DIMENSIONAL PHENOTYPING OF IMMUNE SUBSETS AND CHECKPOINTS IN THE MOUSE GLIOBLASTOMA MICROENVIRONMENT. Neuro-Oncology, 2018, 20, vi127-vi127.	1.2	0